NY A 3833
in committeeRelates to capping cost sharing for antiviral COVID-19 therapeutics
New York · 2025-2026 Regular Session · lower
Quick answers
Did NY A 3833 pass?
Not yet. NY A 3833 is in committee as of 2026-01-07 and has not come to a final vote. Latest recorded action (2026-01-07): REFERRED TO INSURANCE
What is NY A 3833 about?
Requires insurance companies, medical expense indemnity corporations, hospital service corporations, health service corporations and medical assistance programs to provide coverage for prescribed antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the patient.
Who sponsors NY A 3833?
David Weprin is the primary sponsor of NY A 3833.
Description
Requires insurance companies, medical expense indemnity corporations, hospital service corporations, health service corporations and medical assistance programs to provide coverage for prescribed antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the patient.
- Introduced
- —
- Latest action
- 2026-01-07 — REFERRED TO INSURANCE
- Bill type
- bill
- Last updated
- —
Sponsors
- David Weprinprimary
Committees
Not provided by source.
Action timeline
2025-01-30
REFERRED TO INSURANCE
referral-committee
2026-01-07
REFERRED TO INSURANCE
referral-committee
Versions
- A3833Compare
Documents
Votes
Not provided by source.
Related bills
- Prior session: A 9662not in this corpus
Official source
Attribution
Data from openstates_bulk_csv, retrieved 2026-07-24T05:28:30.722574Z
Inspect retained evidence for changes recorded after evidence tracking began:
Session-wide evidence can include changes to other bills:
Use this data
Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=NY&identifier=A 3833. See the API docs or the MCP server for AI assistants.
Known limitations
- Sponsor party and chamber affiliation are not yet captured by this API.
- Committee referrals are not yet captured.
See the methodology page for data sources and limitations.